Bi-specific Chimeric Antigen Receptor for TGF-beta Binding
Summary
USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026, covering a bi-specific chimeric antigen receptor (CAR) that specifically binds TGF-beta. The CAR technology neutralizes TGF-beta while simultaneously triggering T-cell activation, converting an immunosuppressive signal into an activating stimulus. The patent contains 10 claims with application number 17323568, filed May 18, 2021.
What changed
USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026. The patent covers a bi-specific CAR comprising a signal peptide, TGF-beta binding antigen-binding domain, peptide spacer, transmembrane domain, and endodomain. Inventors are Yvonne Yu-Hsuan Chen and Zenan Li Chang. The technology enables cells to neutralize TGF-beta while triggering T-cell activation, turning immunosuppressive signals into activating stimuli for immunotherapy applications.
Entities developing TGF-beta targeting immunotherapies should assess their freedom to operate. Third parties wishing to develop or commercialize TGF-beta targeting CAR therapies may need to obtain licensing from UC. Patent grants do not impose compliance deadlines or penalties on existing market participants, but technology developers should review patent claims to ensure no infringement risk.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Bi-specific chimeric antigen receptor
Grant US12590145B2 Kind: B2 Mar 31, 2026
Assignee
The Regents of the University of California
Inventors
Yvonne Yu-Hsuan Chen, Zenan Li Chang
Abstract
Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen-binding domain that specifically binds TGF-β, a peptide spacer, a transmembrane domain, and an endodomain. When expressed in a cell, the polypeptides are capable of not only neutralizing the TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.
CPC Classifications
C07K 16/22 C07K 14/7051 C07K 2317/33 A61K 39/0008 A61K 2039/5158
Filing Date
2021-05-18
Application No.
17323568
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.